TrialeLife2025

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study.

Yu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.